Skip to content
Incobotulinumtoxina
Xeomin (incobotulinumtoxina) is an unknown pharmaceutical. Incobotulinumtoxina was first approved as Xeomin on 2010-07-30. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Xeomin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Incobotulinumtoxina
Tradename
Proper name
Company
Number
Date
Products
XeominincobotulinumtoxinAMerzN-125360 RX2010-07-30
3 products
Labels
FDA
EMA
Brand Name
Status
Last Update
xeominBiologic Licensing Application2021-04-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
blepharospasm—D001764G24.5
dystoniaHP_0001332D004421G24
fissure in anoHP_0012390D005401K60.2
genetic skin diseases—D012873—
muscle rigidityHP_0002063D009127—
strabismusHP_0000486D013285H50.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINCOBOTULINUMTOXINA
INN—
Description
Botulinum toxin, or botulinum neurotoxin (BoNT), is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It is also known as Botulin, the density of which is predicted to be 1.5±0.1 g/cm3. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
Classification
Neurotoxin
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108035
ChEBI ID—
PubChem CID—
DrugBankDB00083
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 918 documents
View more details
Safety
Black-box Warning
Black-box warning for: Xeomin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,973 adverse events reported
View more details